Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Feasibility of HER2-Directed Targeted Therapy in Patients With Heavily Pretreated HER2-Negative Metastatic Breast Cancer With Elevated Serum Levels of The Soluble HER2 Extracellular Domain and/or HER2-Overexpressing Circulating Tumor Cells

Next Previous
Trial Profile

A Study to Evaluate the Feasibility of HER2-Directed Targeted Therapy in Patients With Heavily Pretreated HER2-Negative Metastatic Breast Cancer With Elevated Serum Levels of The Soluble HER2 Extracellular Domain and/or HER2-Overexpressing Circulating Tumor Cells

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 05 Feb 2016 New trial record
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top